Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32074 | 0.86 | CES2 (0.54) | CES2CES1PTGS2NAAA | |
| SCHEMBL7096425 | 0.86 | CES2 (0.54) | CES2CES1PTGS2NAAA | |
| SCHEMBL3084634 | 0.86 | CES2 (0.54) | CES2CES1PTGS2NAAA | |
| SCHEMBL27952628 | 0.85 | CES2 (0.53) | CES2CES1PTGS2ALDH1A1MAPT | |
| SCHEMBL8092296 | 0.84 | CES2 (0.53) | CES2CES1PTGS2NAAA | |
| SCHEMBL27408372 | 0.83 | CES2 (0.51) | CES2CES1PTGS2NAAAALDH1A1 | |
| SCHEMBL27941243 | 0.83 | CES2 (0.51) | CES2CES1PTGS2ALDH1A1MAPT | |
| Stearic Acid SCHEMBL8430839 | 0.82 | CES2 (0.50) | CES2CES1PTGS2ALDH1A1 | |
| SCHEMBL541541 | 0.81 | LMNA (0.49) | CES2CES1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL27952633 | 0.80 | CES2 (0.54) | CES2CES1PTGS2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9060945-B2 | Use of danielone and derivatives thereof in skin care | DSM IP ASSETS B.V. (NL) | 2015-06-23 | — | — | US | disclosed |
| US-20150004108-A1 | USE OF DANIELONE AND DERIVATIVES THEREOF IN SKIN CARE | DSM IP ASSETS B.V. (NL) | 2015-01-01 | — | — | US | disclosed |
| WO-2013104526-A1 | USE OF DANIELONE AND DERIVATIVES THEREOF IN SKIN CARE | DSM IP ASSETS B.V. (NL) | 2013-07-18 | — | — | WO | disclosed |
| EP-2522330-A1 | Use of resveratrol and an edelweiss extract | DSM IP Assets B.V. (NL) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522332-A1 | Use of resveratrol and magnesium-ascorbyl-phosphate | DSM IP Assets B.V. (NL) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522328-A1 | Use of resveratrol and ascorbyl-2-glucoside | DSM IP Assets B.V. (NL) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522329-A1 | Use of resveratrol and arbutin | DSM IP Assets B.V. (NL) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522335-A1 | Use of resveratrol and sodium-ascorbyl-phophate | DSM IP Assets B.V. (NL) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522331-A1 | Use of resveratrol and niacinamide | DSM IP Assets B.V. (NL) | 2012-11-14 | — | — | EP | disclosed |
| US-20090041687-A1 | Use of opioid receptor antagonists | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| EP-1926490-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSMIP Assets B.V. (NL) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007051596-A1 | NOVEL RETINYL BIOTINATES AND USE THEREOF | DSM IP ASSETS B.V. (NL) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007039058-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | WO | disclosed |
| WO-2004062635-A1 | COMPOSITIONS FOR SKIN LIGHTENING COMPRISING BIS-PANTOYL-CYSTAMINE | DSM IP ASSETS B.V. (NL) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004108-A1 | USE OF DANIELONE AND DERIVATIVES THEREOF IN SKIN CARE | TYR, MITF, MC1R | CES2 2961/4885CES1 1541/4885PTGS2 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.